FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Fok Manson		 2. Issuer Name and Ticker or Trading Symbol

Athenex, Inc. [ ATNX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600		 3. Date of Earliest Transaction (MM/DD/YYYY)

4/21/2023
(Street)

BUFFALO, NY 14203		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 4/21/2023  A  5747 A$1.305 (1)110675 (2)D  
Common Stock         33944 (2)I (3)(4)By Avalon Biomedical (Management) Limited (3)(4)
Common Stock         5360 (2)(5)I (3)(4)(5)By Avalon Polytom (HK) Limited (3)(4)(5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $91.00 (6)          5/13/2014 5/13/2023 Common Stock 2400 (6) 2400 (6)D  
Stock Option (Right to Buy) $91.00 (6)          10/11/2015 10/11/2023 Common Stock 1000 (6) 1000 (6)D  
Stock Option (Right to Buy) $91.00 (6)          6/12/2016 6/12/2024 Common Stock 2000 (6) 2000 (6)D  
Stock Option (Right to Buy) $150.00 (6)          5/18/2016 5/18/2025 Common Stock 2400 (6) 2400 (6)D  
Stock Option (Right to Buy) $180.00 (6)          10/17/2017 10/17/2025 Common Stock 2400 (6) 2400 (6)D  
Stock Option (Right to Buy) $220.00 (6)          6/13/2021 6/13/2027 Common Stock 1350 (6) 1350 (6)D  
Stock Option (Right to Buy) $180.00 (6)          7/17/2018 7/17/2025 Common Stock 2746 (6) 2746 (6)I (3)(4)By Avalon Biomedical (Management) Limited (3)(4)
Stock Option (Right to Buy) $346.00 (6)          3/27/2022 3/27/2028 Common Stock 750 (6) 750 (6)D  
Stock Option (Right to Buy) $263.40 (6)          2/28/2023 2/28/2029 Common Stock 500 (6) 500 (6)D  
Stock Option (Right to Buy) $249.00 (6)           (7)6/5/2030 Common Stock 500 (6) 500 (6)D  
Stock Option (Right to Buy) $76.00 (6)          8/3/2022 8/3/2031 Common Stock 313 (6) 313 (6)D  
Stock Option (Right to Buy) $9.14 (6)           (8)6/28/2032 Common Stock 625 (6) 625 (6)D  
Explanation of Responses:
(1) Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
(2) As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.
(3) Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mason Fok, M.B., B.S. ("Dr. Fok"), together with his spouse, own all of the outstanding interests in Sino Glory Developments Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Fok serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
(4) Dr. Fok disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Fok is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(5) These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
(6) This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.
(7) This option vests in four equal annual installments beginning on June 5, 2021.
(8) This option vests on June 28, 2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Fok Manson
C/O ATHENEX, INC.
1001 MAIN STREET, SUITE 600
BUFFALO, NY 14203		X
Signatures
/s/ Staci Holquist, Attorney-in-Fact4/24/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Athenex Charts.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Athenex Charts.